InterPAD - DETAILS

Repaglinide, 135062-02-1, Prandin, NovoNorm, GlucoNorm, AG-EE 623 ZW, Repaglinidum, Repaglinida, AG-EE 388 ZW, Repaglinidum [INN-Latin], Repaglinida [INN-Spanish], AGEE-623ZW, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, Surepost, Reglin, C27H36N2O4, AG-EE-623ZW, NSC-759893, UNII-668Z8C33LU, AG-EE-623-ZW, DTXSID3023552, A10BX02, 668Z8C33LU, (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid, CHEMBL1272, (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid, (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid, CHEBI:8805, DTXCID603552, (-)-Repaglinide, Repaglinide [USAN:USP:INN:BAN], MFCD00906179, 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid, NSC 759893, NCGC00016978-01, Repaglinide [USAN], repa-glinide, CAS-135062-02-1, Repaglinidum (INN-Latin), Repaglinida (INN-Spanish), REPAGLINIDE (MART.), REPAGLINIDE [MART.], REPAGLINIDE (USP-RS), REPAGLINIDE [USP-RS], 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid, Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-, Actulin, REPAGLINIDE (EP MONOGRAPH), REPAGLINIDE [EP MONOGRAPH], REPAGLINIDE (USP MONOGRAPH), REPAGLINIDE [USP MONOGRAPH], Repaglinide (USAN:USP:INN:BAN), (+)-repaglinide, (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID, (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid, 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid, SMR000466305, Prandin (TN), AG-EE 623ZW, Repaglinide (JAN/USP/INN), AG-EE-623 ZW, AG-EE-388, Repaglinide,(S), SMP-508, Surepost (TN), BJX, Repaglinide- Bio-X, NN-623, (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, 111GE012, REPAGLINIDE [MI], Prestwick0_001046, Prestwick1_001046, Prestwick2_001046, Prestwick3_001046, REPAGLINIDE [INN], REPAGLINIDE [JAN], REPAGLINIDE [VANDF], (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, SCHEMBL16137, BSPBio_000972, REPAGLINIDE [WHO-DD], MLS000759407, MLS001076684, MLS001424111, MLS006011560, BIDD:GT0338, SPBio_002906, REPAGLINIDE [EMA EPAR], BPBio1_001070, GTPL6841, REPAGLINIDE [ORANGE BOOK], Repaglinide for system suitability, HMS1571A14, HMS2051N08, HMS2094C07, HMS2098A14, HMS2231M21, HMS3414D09, HMS3678D09, HMS3715A14, Pharmakon1600-01506035, BCP04250, Tox21_110721, AC-726, BDBM50153520, HB1106, NSC759893, s1426, STK629501, AKOS005561792, Repaglinide, >=98% (HPLC), solid, BS-1010, CCG-101013, CS-0979, DB00912, NC00263, NCGC00016978-02, NCGC00016978-04, NCGC00016978-05, NCGC00016978-15, BR164332, HY-15209, SBI-0206942.P001, AB00514019, AM20090697, FT-0631150, FT-0674344, FT-0674345, R0179, SW197344-4, C07670, D00594, F15001, AB00514019-09, AB00514019_10, AB00514019_11, A806877, SR-01000759404, Q-201663, Q2195995, SR-01000759404-4, BRD-K82846253-001-03-0, Z1501485370, Repaglinide, European Pharmacopoeia (EP) Reference Standard, Repaglinide, United States Pharmacopeia (USP) Reference Standard, (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid, (S)-2-Ethoxy-4-(2-(3-methyl-1-(2-piperidinophenyl)butylamino)-2-oxoethyl)benzoic acid, Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard, (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID, (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-4-carboxy-butanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pe;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid, (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid, 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid, 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid, Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-, Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-

Name	Repaglinide
PubChem CID	65981
Molecular Weight	452.6g/mol
Synonyms	Repaglinide, 135062-02-1, Prandin, NovoNorm, GlucoNorm, AG-EE 623 ZW, Repaglinidum, Repaglinida, AG-EE 388 ZW, Repaglinidum [INN-Latin], Repaglinida [INN-Spanish], AGEE-623ZW, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, Surepost, Reglin, C27H36N2O4, AG-EE-623ZW, NSC-759893, UNII-668Z8C33LU, AG-EE-623-ZW, DTXSID3023552, A10BX02, 668Z8C33LU, (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid, CHEMBL1272, (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid, (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid, CHEBI:8805, DTXCID603552, (-)-Repaglinide, Repaglinide [USAN:USP:INN:BAN], MFCD00906179, 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid, NSC 759893, NCGC00016978-01, Repaglinide [USAN], repa-glinide, CAS-135062-02-1, Repaglinidum (INN-Latin), Repaglinida (INN-Spanish), REPAGLINIDE (MART.), REPAGLINIDE [MART.], REPAGLINIDE (USP-RS), REPAGLINIDE [USP-RS], 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid, Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-, Actulin, REPAGLINIDE (EP MONOGRAPH), REPAGLINIDE [EP MONOGRAPH], REPAGLINIDE (USP MONOGRAPH), REPAGLINIDE [USP MONOGRAPH], Repaglinide (USAN:USP:INN:BAN), (+)-repaglinide, (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID, (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid, 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid, SMR000466305, Prandin (TN), AG-EE 623ZW, Repaglinide (JAN/USP/INN), AG-EE-623 ZW, AG-EE-388, Repaglinide,(S), SMP-508, Surepost (TN), BJX, Repaglinide- Bio-X, NN-623, (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, 111GE012, REPAGLINIDE [MI], Prestwick0_001046, Prestwick1_001046, Prestwick2_001046, Prestwick3_001046, REPAGLINIDE [INN], REPAGLINIDE [JAN], REPAGLINIDE [VANDF], (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, SCHEMBL16137, BSPBio_000972, REPAGLINIDE [WHO-DD], MLS000759407, MLS001076684, MLS001424111, MLS006011560, BIDD:GT0338, SPBio_002906, REPAGLINIDE [EMA EPAR], BPBio1_001070, GTPL6841, REPAGLINIDE [ORANGE BOOK], Repaglinide for system suitability, HMS1571A14, HMS2051N08, HMS2094C07, HMS2098A14, HMS2231M21, HMS3414D09, HMS3678D09, HMS3715A14, Pharmakon1600-01506035, BCP04250, Tox21_110721, AC-726, BDBM50153520, HB1106, NSC759893, s1426, STK629501, AKOS005561792, Repaglinide, >=98% (HPLC), solid, BS-1010, CCG-101013, CS-0979, DB00912, NC00263, NCGC00016978-02, NCGC00016978-04, NCGC00016978-05, NCGC00016978-15, BR164332, HY-15209, SBI-0206942.P001, AB00514019, AM20090697, FT-0631150, FT-0674344, FT-0674345, R0179, SW197344-4, C07670, D00594, F15001, AB00514019-09, AB00514019_10, AB00514019_11, A806877, SR-01000759404, Q-201663, Q2195995, SR-01000759404-4, BRD-K82846253-001-03-0, Z1501485370, Repaglinide, European Pharmacopoeia (EP) Reference Standard, Repaglinide, United States Pharmacopeia (USP) Reference Standard, (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid, (S)-2-Ethoxy-4-(2-(3-methyl-1-(2-piperidinophenyl)butylamino)-2-oxoethyl)benzoic acid, Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard, (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID, (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-4-carboxy-butanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pe;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid, (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid, 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid, 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid, Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-, Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-
Drug Type	Small molecule
Formula	C₂₇H₃₆N₂O₄
SMILES	CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
InChI	1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
InChIKey	FAEKWTJYAYMJKF-QHCPKHFHSA-N
CAS Number	135062-02-1
ChEMBL ID	CHEMBL1272
ChEBI ID	CHEBI:8805
TTD ID	D0N5YA
Drug Bank ID	DB00912
KEGG ID	D00594
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Repaglinide
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.